Literature DB >> 2441737

Screening for Down's syndrome using an iso-risk curve based on maternal age and serum alpha-fetoprotein level.

A Tabor, S O Larsen, J Nielsen, J Nielsen, J Philip, B Pilgaard, P Videbech, B Nørgaard-Pedersen.   

Abstract

On the basis of the significantly different distributions of maternal serum alpha-fetoprotein (AFP) levels in 86 pregnancies associated with fetal Down's syndrome and in 2018 unaffected pregnancies, an iso-risk curve for Down's syndrome was constructed. An iso-risk curve shows, for women of all ages, which combinations of maternal age and level of maternal serum AFP result in the same risk of carrying a fetus with Down's syndrome. A 1:400 risk of Down's syndrome, corresponding to the risk of a 35-year-old woman, was chosen as the lowest risk indicating referral for amniocentesis. If all women, irrespective of their age, are offered amniocentesis, when their risk of carrying a Down's syndrome fetus is 1:400 or higher, 53% of the affected fetuses can be detected as compared with 28% of the affected fetuses diagnosed at present in women above 35 years of age.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441737     DOI: 10.1111/j.1471-0528.1987.tb03167.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  11 in total

1.  Screening for Down syndrome.

Authors:  N J Wald; H S Cuckle; J Sneddon; J E Haddow; G E Palomaki
Journal:  Am J Hum Genet       Date:  1989-04       Impact factor: 11.025

2.  Variability in MSAFP predicted rates of Down syndrome.

Authors:  J N Macri; D A Krantz; E J Cook; K Sorensen; R V Kasturi
Journal:  Am J Hum Genet       Date:  1989-02       Impact factor: 11.025

Review 3.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 5.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

6.  Immunochemical quantification of Cu/Zn superoxide dismutase in prenatal diagnosis of Down's syndrome.

Authors:  T Porstmann; R Wietschke; G Cobet; K Lorenz; R Grunow; S Jahn; R Bollmann; G Stamminger; R von Baehr
Journal:  Hum Genet       Date:  1990-08       Impact factor: 4.132

7.  Variability in predicted rates of Down syndrome associated with elevated maternal serum alpha-fetoprotein levels in older women.

Authors:  E B Hook
Journal:  Am J Hum Genet       Date:  1988-08       Impact factor: 11.025

8.  Maternal levels of pregnancy-specific beta 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome.

Authors:  I Bartels; A Lindemann
Journal:  Hum Genet       Date:  1988-09       Impact factor: 4.132

Review 9.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 10.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.